STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more

Good morning, and welcome back to another busy week. It seems the weekend has provided a much-needed break from the usual grind of work and responsibilities. To help get through the upcoming days, many are reaching for a comforting cup of blueberry hibiscus tea. There's no need for a prescription or prior authorization to enjoy this soothing beverage.

In other news, AstraZeneca reported a setback with their breast cancer medication, camizestrant. When tested as a first-line therapy for advanced tumors, the drug failed to outperform standard treatments. This outcome may limit the drug's potential market, as it had previously received accelerated approval in the U.S. for patients with specific tumor mutations. If the trial had been successful, it could have expanded the drug's reach significantly.

Meanwhile, Scholar Rock received FDA approval for a groundbreaking therapy targeting muscle loss in spinal muscular atrophy (SMA). The drug, Isembyld, is now available for adults and children aged 2 and above who are already undergoing SMA treatments that target the SMN2 gene. This approval brings hope to patients with this rare and progressive neurological disorder, which often leads to death by the age of 2 if left untreated.